人類肝臟模型市場規模、佔有率和成長分析（按產品類型、應用、最終用戶和地區分類）—2026-2033年產業預測

全球人類肝臟模型市場規模預計在 2024 年達到 13.8 億美元，從 2025 年的 15.8 億美元成長到 2033 年的 47.3 億美元，在預測期（2026-2033 年）內複合年成長率為 14.7%。

全球人工肝模型市場預計將迎來顯著成長，主要受藥物毒性測試需求不斷成長以及減少動物實驗的強烈推動。再生醫學投資的增加和3D肝臟建模技術的進步也促進了這一成長。此外，肝臟疾病盛行率的上升以及對個人化醫療日益成長的關注，也加劇了對準確可靠的藥物測試替代方案的需求。儘管前景光明，但仍存在諸多挑戰，例如高成本、熟練人員短缺以及先進肝臟建模技術實施的複雜性。此外，監管障礙和模型檢驗的不一致可能會阻礙其廣泛應用，進而影響區域市場滲透率和成長率。

全球人工肝模型市場促進因素

對藥物毒性進行精準快速評估的需求日益成長，是推動人類肝臟模型市場擴張的關鍵因素。這些模型具有更高的生理相關性和預測準確性，使製藥公司能夠在研發過程的早期階段發現潛在的毒性。這項重要特性增強了藥物候選物在各個研發階段的推進信心，最終有助於更有效率、更有效地進行藥物評估和核准。因此，製藥業對改進調查方法的需求正在顯著推動人類肝臟模型市場的成長。

限制全球人類肝臟模型市場的因素

全球人類肝臟模型市場面臨的挑戰在於，建造和維護先進的肝臟模型（包括晶片肝臟系統和3D列印組織）需要大量的資金投資。對專用設備、高技能人員和高品質材料的需求會導致高昂的成本，這對於預算有限的小規模實驗室和機構而言難以承受。這種經濟負擔會阻礙市場進入和普及，尤其是在資源匱乏的發展中地區，從而限制了能夠促進該領域研發的創新技術的應用。

全球人類肝臟模型市場趨勢

受3D生物列印和晶片器官平台等技術進步的推動，全球人類肝臟模型市場正經歷顯著成長。這些創新技術提高了藥物篩檢的準確性，減少了對傳統動物實驗的依賴，並能更精確地模擬複雜的肝臟疾病。這項發展不僅簡化了藥物發現和開發流程，也有助於更有效地進行疾病研究，使人類肝臟模型成為製藥和生物醫學領域不可或缺的工具。此外，人們日益重視緩解與動物模型相關的倫理問題，進一步推動了對這些先進肝臟模型的需求，從而為市場帶來了光明的前景。

目錄

介紹

• 調查目標
• 調查範圍
• 定義

調查方法

• 資訊收集
• 二手資料和一手資料方法
• 市場規模預測
• 市場假設與限制

執行摘要

• 全球市場展望
• 供需趨勢分析
• 細分市場機會分析

市場動態與展望

• 市場規模
• 市場動態
  • 促進因素和機遇
  • 限制與挑戰
• 波特分析

關鍵市場考察

• 關鍵成功因素
• 競爭程度
• 關鍵投資機會
• 市場生態系統
• 市場吸引力指數（2025）
• PESTEL 分析
• 總體經濟指標
• 價值鏈分析
• 定價分析
• 技術評估
• 監管環境

全球人類肝臟模型市場規模（按產品類型和複合年成長率分類）（2026-2033 年）

• 2D模型
• 3D模型
• 晶片肝臟/微流體模型
• 離體/組織切片模型

全球人類肝臟模型市場規模（按應用及複合年成長率分類）（2026-2033 年）

• ADME 研究
• 毒理學/安全性測試
• 疾病模型
• 其他

全球人類肝臟模型市場規模（按最終用戶和複合年成長率分類）（2026-2033 年）

• 製藥和生物技術公司
• 受託研究機構（CRO）
• 學術和研究機構

全球人類肝臟模型市場規模及複合年成長率（2026-2033）

• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 西班牙
  • 法國
  • 英國
  • 義大利
  • 其他歐洲地區
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 韓國
  • 亞太其他地區
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲地區
• 中東和非洲
  • 海灣合作理事會國家
  • 南非
  • 其他中東和非洲地區

競爭資訊

• 前五大公司對比
• 主要企業的市場定位（2025 年）
• 主要市場參與者所採取的策略
• 近期市場趨勢
• 公司市佔率分析（2025 年）
• 主要企業公司簡介
  • 公司詳情
  • 產品系列分析
  • 依業務板塊進行公司股票分析
  • 2023-2025年營收年比比較

主要企業簡介

• ATCC
• Merck KGaA
• AcceGen
• ZenBio, Inc.
• Organovo Holdings Inc.
• BioIVT
• InSphero
• CN Bio Innovations Ltd.
• STEMCELL Technologies
• ScienCell Research Laboratories, Inc.
• Emulate, Inc.
• Cyfuse Biomedical KK
• Mimetas
• Cellink
• PhoenixBio Co., Ltd.
• Thermo Fisher Scientific Inc.
• BICO Group
• Kirkstall Ltd.
• MATTEK（The BICO Group）
• HiREL

結論與建議

Global Human Liver Models Market size was valued at USD 1.38 Billion in 2024 and is poised to grow from USD 1.58 Billion in 2025 to USD 4.73 Billion by 2033, growing at a CAGR of 14.7% during the forecast period (2026-2033).

The global human liver model market is poised for significant growth, driven by heightened demand for drug toxicity testing and a strong push towards minimizing animal testing. Factors such as increased investments in regenerative medicine and advancements in 3D liver modeling technologies are contributing to this expansion. Furthermore, the rising prevalence of liver diseases and the growing emphasis on personalized medicine are amplifying the necessity for precise and dependable drug testing alternatives. Despite this promising outlook, challenges remain, including the high costs associated with advanced liver model technologies, a shortage of skilled personnel, and the complex nature of implementation. Additionally, regulatory hurdles and inconsistencies in model validation may impede widespread adoption, potentially affecting market penetration and growth rates in various regions.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Human Liver Models market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Human Liver Models Market Segments Analysis

Global Human Liver Models Market is segmented by Product Type, Application, End-User and region. Based on Product Type, the market is segmented into 2D Models, 3D Models, Liver-on-a-Chip / Micro-fluidic Models and Ex-Vivo / Tissue Slice Models. Based on Application, the market is segmented into ADME Studies, Toxicology / Safety Testing, Disease Modelling and Others. Based on End-User, the market is segmented into Pharmaceutical & Biotechnology Companies, Contract Research Organisations (CROs) and Academic & Research Institutes. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Human Liver Models Market

The increasing need for precise and prompt assessment of drug toxicity serves as a significant catalyst for the expansion of the human liver models market. These models provide enhanced physiological relevance and predictive accuracy, enabling pharmaceutical companies to detect potential toxicities earlier in the development process. This crucial capability allows for greater confidence in advancing drug candidates through various stages of development, ultimately contributing to more efficient and effective drug evaluation and approval. As a result, the market for human liver models is witnessing considerable growth, driven by the necessity for improved testing methodologies in the pharmaceutical industry.

Restraints in the Global Human Liver Models Market

The Global Human Liver Models market faces challenges due to the substantial financial investments required for the creation and maintenance of advanced liver models, including liver-on-a-chip systems and three-dimensional printed tissues. The need for specialized equipment, a highly skilled workforce, and quality materials can lead to significant costs that may be overwhelming for smaller laboratories or institutions with limited budgets. This financial burden can hinder market entry and accessibility, particularly in developing regions where resources are scarce, thus restricting the adoption of innovative technologies that could otherwise enhance research and development in the field.

Market Trends of the Global Human Liver Models Market

The Global Human Liver Models market is witnessing significant growth driven by technological advancements in 3D bioprinting and organ-on-a-chip platforms. These innovations enhance the precision of drug screening processes, minimizing reliance on traditional animal testing and enabling researchers to replicate intricate liver diseases more accurately. This evolution not only streamlines drug discovery and development but also supports more effective disease research, positioning human liver models as essential tools in pharmaceutical and biomedical fields. The emphasis on reducing ethical concerns associated with animal models further fuels the demand for these sophisticated liver models, indicating a promising trajectory for the market.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2025
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis
• Technology Assessment
• Regulatory Landscape

Global Human Liver Models Market Size by Product Type & CAGR (2026-2033)

• Market Overview
• 2D Models
• 3D Models
• Liver-on-a-Chip / Micro-fluidic Models
• Ex-Vivo / Tissue Slice Models

Global Human Liver Models Market Size by Application & CAGR (2026-2033)

• Market Overview
• ADME Studies
• Toxicology / Safety Testing
• Disease Modelling
• Others

Global Human Liver Models Market Size by End-User & CAGR (2026-2033)

• Market Overview
• Pharmaceutical & Biotechnology Companies
• Contract Research Organisations (CROs)
• Academic & Research Institutes

Global Human Liver Models Market Size & CAGR (2026-2033)

• North America (Product Type, Application, End-User)
  • US
  • Canada
• Europe (Product Type, Application, End-User)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Product Type, Application, End-User)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Product Type, Application, End-User)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Product Type, Application, End-User)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2025
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2025
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

• ATCC
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck KGaA
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AcceGen
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• ZenBio, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Organovo Holdings Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• BioIVT
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• InSphero
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• CN Bio Innovations Ltd.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• STEMCELL Technologies
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• ScienCell Research Laboratories, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Emulate, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Cyfuse Biomedical K.K.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Mimetas
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Cellink
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• PhoenixBio Co., Ltd.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Thermo Fisher Scientific Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• BICO Group
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Kirkstall Ltd.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• MATTEK (The BICO Group)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• HiREL
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations